An Ideal Detector Composed of Two-Dimensional Cd(II)-Triazole Frameworks for Nitro-Compound Explosives and Potassium Dichromate.

The two-dimensional (2D) metal-organic framework (MOF) [Cd(TPTZ)(H2O)2(HCOOH)(IPA)2]n (1; TPTZ = {4-[4-(1H-1,2,4-triazol-1-yl)phenyl]phenyl}-1H-1,2,4-triazole, IPA = isophthalic acid) has been constructed with the π-electron-rich aromatic ligand TPTZ, auxiliary ligand IPA, and the metal Cd(2+) ion with a d(10) configuration under solvothermal conditions. Complex 1 exhibits a strong ligand-originated photoluminescence emission, which is selectively sensitive toward electron-deficient nitroaromatic compounds, such as nitrobenzene (NB), 1,3-dinitrobenzene (m-DNB), and 1,4-dinitrobenzene (p-DNB), and nitro-aliphatic compounds, such as nitromethane (NM) and tris(hydroxymethyl)nitromethane. This property makes complex 1 a potential fluorescence sensor for these chemicals. Single-crystal X-ray diffraction studies revealed that dinuclear cadmium building units were further bridged by TPTZ ligands to give a four-connected uninodal net with the Schläfli symbol of [4.6(3).4.6(3).6(2).6(4)].

Cation-Exchange Porosity Tuning in a Dynamic 4d-4f-3d Framework for Ni(II) Ion-Selective Luminescent Probe.

A heterometallic complex {[Yb2(L)6Cd2][Cd(H2O)6]·6H2O}n (Yb-Cd) (H2L = oxidiacetic acid) was synthesized under hydrothermal conditions. In Yb-Cd, each L chelates to one Yb(3+) center and bonds to two Cd(2+) ions in an anti-anti configuration. Yb and Cd atoms are arrayed alternatively and connected by O-C-O bridges to form a cubic octahedral cage as the secondary building unit. Consequently, topological NaCl nets with high symmetry in the cubic space group Fd-3c have been constructed. The [Cd(H2O)6](2+) moieties lying in the porosity of anionic metal-organic framework (MOF) act as the thermodynamically stable species, required to balance the two negative charges of [Yb2(L)6Cd2](2-) in Yb-Cd. Interestingly, when Yb-Cd was employed as a precursor and emerged in the aqueous solution of Mn(ClO4)2·6H2O or Zn(ClO4)2·6H2O, a reversible single-crystal-to-single-crystal transformation process driven by [Cd(H2O)6](2+) cations has been exhibited to generate the heterotrimetallic coordination polymer {[Yb2(L)6Cd2][Mn(H2O)6]·6H2O}n (Yb-Cd-Mn) or {[Yb2(L)6Cd2][Zn(H2O)6]·6H2O}n (Yb-Cd-Zn). To the best of out knowledge, Yb-Cd-Mn and Yb-Cd-Zn are the first examples representing 4d-4f-3d polymers based on multicarboxylic acid. Luminescent studies reveal that Yb-Cd-Zn may serve as a good candidate of Ni(2+) a luminescent probe. To our knowledge, Yb-Cd-Zn represent the fist example of the 4d-4f-3d framework to exhibit luminescent selectivity for Ni(2+).

The strategy and efficacy of prophylaxis against hepatitis B virus recurrence after liver transplantation for HBV-related diseases in the era of potent nucleos(t)ide analogues: A meta-analysis.

OBJECTIVES: This meta-analysis aimed to evaluate the clinical outcome of liver transplant (LT) recipients under potent nucleoside or nucleotide analogue (NA)-based regimens and investigate different prophylactic schemes. METHODS: We followed PRISMA statement to conduct this study. Two reviewers independently searched relevant literature via PubMed, Embase, Ovid MEDLINE, Web of Science and Insightmeme. Studies were included if they evaluated hepatitis B virus (HBV) recurrence under potent NA-based regimens in patients who received HBV-related LT. Primary and secondary outcomes were HBV recurrence, hepatocellular carcinoma (HCC) recurrence, all-cause and HBV recurrence-related mortality. Incidences with 95% confidence intervals were calculated and assessed by fixed and random effects models. Subgroup analyses were used to examine the impact of different treatment strategies. RESULTS: Altogether 25 studies (N = 2327) were included, with a pooled HBV recurrence rate of 1.01% (95% CI 0.53%-1.59%). HBV viremia or hepatitis D virus superinfection did not influence HBV recurrence significantly (P = 0.23 and 0.71, respectively). The recurrence rate under an indefinite combination of potent NA and hepatitis B immunoglobulin (HBIG) was lower than that under potent NA monotherapy (P = 0.000) and similar to that under NA plus a finite course of HBIG (P = 0.48). The pooled HCC recurrence rate was 5.34% (95% CI 0.78%-12.48%). HBV recurrence-related mortality and all-cause mortality were 0% and 6.95% (95% CI 4.30%-10.08%), respectively. CONCLUSIONS: Potent NA-based regimens provide satisfactory HBV antiviral prophylaxis and improve long-term outcomes for LT recipients. A finite combination of potent NA and HBIG is an alternative to life-long dual therapy.

Valproic acid's effects on visual acuity in retinitis pigmentosa: a systemic review and Meta-analysis.

AIM: To gain a better understanding of the overall efficacy of valproic acid (VPA) treatment for retinitis pigmentosa (RP). METHODS: Publications in PubMed, EMBASE, Cochrane Library, Web of Science and Clinicaltrials.gov were searched for clinical trials of patients with RP assigned to treatment with VPA. Patients' pre- and post-treatment visual field (VF) and best-corrected visual acuity (BCVA) scores were extracted and compared to assess changes. RESULTS: A total of 78 reports were retrieved and 6 studies involving 116 patients were included in the Meta-analysis. The combined results showed a significant decrease in logarithm of minimal angle of resolution (logMAR) scores, calculated using baseline and post-treatment BCVA (P<0.00001, mean difference=-0.05, 95%CI: -0.05, -0.04, I 2=36%) scores, which means there was considerable improvement in visual acuity. Meanwhile, more BCVA changes were observed in short-term (≤6mo) treatment studies (P<0.00001, mean difference=-0.05, 95%CI: -0.05, -0.04, I 2=38%), studies conducted in Asia (P<0.00001, mean difference=-0.05, 95%CI: -0.05, -0.04, I 2=4%), studies with a sample size of 30 or fewer patients (P<0.00001, mean difference=-0.05, 95%CI: -0.05, -0.04, I 2=38%) and prospective studies (P<0.00001, mean difference=-0.05, 95%CI: -0.05, -0.04, I 2=0%). However, VPA's effect on VF was inconsistent across studies (P=0.75, mean difference=-22.76, 95%CI: -160.56, 115.05, I 2=68%). CONCLUSION: This Meta-analysis reveals that most RP patients who were treated with VPA showed improvement in BCVA. However, its effect on VF remains inconsistent. VPA may be a promising treatment for RP.